ArticleInfection and drug resistance2019
Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance.Interdisciplinary perspectives on infectious diseases · 2026Review
- Efficacy of ceftazidime-avibactam for the treatment of central nervous system infection caused by carbapenem-resistantFrontiers in neurology · 2025Article
- Community-acquired multidrug-resistantIDCases · 2024Article
- Treatment of Ventriculitis and Meningitis After Neurosurgery Caused by Carbapenem-ResistantInfection and drug resistance · 2023Review
- Therapeutic Options and Outcomes for the Treatment of Neonates and Preterms with Gram-Negative Multidrug-Resistant Bacteria: A Systematic Review.Antibiotics (Basel, Switzerland) · 2022Review
- Intrathecal Antibacterial and Antifungal Therapies.Clinical microbiology reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Enterobacteriaceae (CRE) meningitis are associated with poor outcomes and high mortality. Here, we report the first successful treatment case of serious meningitis caused by extremely carbapenem-resistant CASE PRESENTATION: A 17-year-old girl developed meningitis from an extremely carbapenem-resistant
conclusionThis case report shows the possibility of the antibiotic regimen of high-dose prolonged infusion of meropenem and i.v. amikacin plus IVT amikacin in the successful treatment of CRE meningitis (MIC of imipenem ≥16mg/L) especially when other antibiotics are unavailable or restricted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.